Thank you # WSPH for another inspiring and engaging congress full of knowledge-sharing, connection-making and community-building. It's always a highlight to meet others from the community and spend time learning from each other and sharing updates. #PulmonaryHypertension
Gossamer Bio
Biotechnology Research
San Diego, California 10,294 followers
Vision * Connection * Innovation
About us
Gossamer Bio is a San Diego-based clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Our goal is to enhance the lives of people living with pulmonary hypertension.
- Website
-
http://www.gossamerbio.com
External link for Gossamer Bio
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Founded
- 2017
- Specialties
- Pulmonary hypertension
Locations
-
Primary
3013 Science Park Rd
Suite 200
San Diego, California 92121, US
-
77 Sir John Rogerson's Quay
Block C - Suite 210-212
Dublin City, County Dublin D02, IE
Employees at Gossamer Bio
Updates
-
Don't miss our 3 posters at the World Symposium on Pulmonary Hypertension (WSPH) 2024 this Sunday! You can visit the posters all day. Swipe below to read the exciting work Gossamer Bio is presenting. #WSPH2024 #PulmonaryArterialHypertension #PulmonaryHypertension #GossamerBio
-
The World Symposium on Pulmonary Hypertension (WSPH) is finally here and Gossamer Bio is delighted to attend! Join us alongside the world’s leading experts in pulmonary hypertension, from top physicians and researchers to dedicated patient organisations. We’re excited to share insights, forge connections, and discover groundbreaking advancements. Faheem Hasnain, Co-Founder, Chairman, and CEO, would like to share his special thanks to the organising committee for making this event possible. For more information, please visit www.wsph2024.com #WSPH2024 #PulmonaryHypertension #GossamerBio
-
Don't miss our 2 posters at the World Symposium on Pulmonary Hypertension (WSPH) 2024 this Saturday! You can visit the posters all day. Swipe below to read the exciting work Gossamer Bio is presenting. #WSPH2024 #PulmonaryArterialHypertension #PulmonaryHypertension #GossamerBio
-
Excitement is building as we approach the World Symposium on Pulmonary Hypertension (WSPH), the largest scientific PH event globally, held only once every 5 years, bringing together the brightest minds in science, research, clinical and industry. This year marks a significant milestone for Patient Advocacy Groups, with the opening "Patient Perspectives" session at 9:15 am, Saturday the 29th. What a huge step forward for patient representation! We can’t wait to see you there! For more information, please visit www.wsph2024.com #WSPH2024 #PulmonaryHypertension #PatientAdvocacy #GossamerBio
-
🚨 Don't miss our two poster presentations at the American Thoracic Society (ATS) 2024 International Conference today! The sessions will start at 11:00am PT. Full details included below 👇 #PAH #PulmonaryArterialHypertension #PulmonaryHypertension
-
@BiotechTV 𝐀𝐓𝐒 𝟐𝟎𝟐𝟒: Gossamer Bio presented open label extension data for seralutinib, an inhibitor of PDGFR, CSF1R, and c-KIT, in PAH showing durability of effect at 72 weeks. CEO Faheem Hasnain and trial investigator Olivier SITBON describe how some patients seem to not just be maintaining benefit, but improving at 72 weeks vs 24 weeks. Mr. Hasnian also recaps a transformative partnership with Chiesi that was announced earlier this month. hashtag#ATS2024 Full video: https://loom.ly/_s7b1U8
-
We’re excited to see you in San Diego at the 2024 International Conference of the American Thoracic Society #ATS2024! You can read the full details here: https://loom.ly/lyoBXb0 #PAH #PulmonaryArterialHypertension #PulmonaryHypertension